Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects

被引:32
作者
Chrousos, GP [1 ]
Ghaly, L
Shedden, A
Iezzoni, DG
Harris, AG
机构
[1] Univ Athens, Sch Med, Dept Pediat 1, Aghia Sophia Childrens Hosp, GR-11527 Athens, Greece
[2] Integrated Therapeut Grp, Kenilworth, NJ USA
关键词
asthma; beclomethasone dipropionate; corticosteroid; hypothalamo-hypophyseal system; mometasone furoate;
D O I
10.1378/chest.128.1.70
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objectives: Mometasone furoate dry powder inhaler (MF-DPI) [400 mu g] is an inhaled corticosteroid (ICS) that is effective in the treatment of asthma. MF-DPl has a low potential for suppression of the hypothalamic-pituitary-adrenal (HPA) axis at its clinical dose. The effect of MF-DPI, 400 mu g qd, on the UPA axis was compared to that of beclomethasone dipropionate (BDP) using hydrofluoroalkane, (HFA) and chlorofluorocarbon (CFC) propellants via metered-dose inhalers (MDIs) twice daily. Design and interventions: This randomized, third-party blind, parallel-group study compared the effects of MF-DPl 400 mu g one puff qd in the morning (n 18), HFA-BDP 200 mu g two puffs MDI bid (n = 18), and CFC-BDP 400 mu g two puffs MDI bid (n 17) for 14 days on the area under the 24-h serum cortisol concentrations curve (AUC(0-24)) and on total 24-h urinary free cortisol excretion in mild asthmatic subjects. Effects on morning/evening peak expiratory How (PEF) and on inhaled albuterol use were also assessed. Adverse events that occurred during or >= 30 days after the study were recorded. Results: The mean decrease from baseline in the serum cortisol concentrations AUC(0-24) in the MF-DPI group was significantly less than in either the HFA-BDP (p = 0.024) or the CFC-BDP (p = 0.011) groups. Decreases in serum cortisol concentrations AUC(0-24) in the two BDP groups did not differ from one another. The MF-DPI group trended toward higher morning and evening PEF than either BDP group. Treatment-associated adverse events were reported by seven subjects in the MF-DP1 group, vs one subject in the HFA-BDP and three subjects in the CFC-BDP groups; these were mild, and no subject discontinued treatment due to an adverse event. Conclusions: Fourteen days of treatment with MF-DP1 400 mu g qd was associated with a significantly lesser decrease in the serum cortisol concentrations AUC(0-24) compared With HFA-BDP 200 mu g MDI or CFC-BDP 400 mu g MDI bid.
引用
收藏
页码:70 / 77
页数:8
相关论文
共 27 条
  • [21] Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma
    Li, JTC
    Ford, LB
    Chervinsky, P
    Weisberg, SC
    Kellerman, DJ
    Faulkner, KG
    Herje, NE
    Hamedani, A
    Harding, SM
    Shah, T
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (06) : 1062 - 1068
  • [22] Effects of budesonide by means of the turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects:: A dose-response study
    Aaronson, D
    Kaiser, H
    Dockhorn, R
    Findlay, S
    Korenblat, P
    Thorsson, L
    Källén, A
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (03) : 312 - 319
  • [23] Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled and nasal corticosteroids: is the early-morning serum adrenocorticotropic hormone (ACTH) a useful screening test?
    Zoellner, Ekkehard W.
    Lombard, Carl
    Galal, Ushma
    Hough, Stephen
    Irusen, Elvis
    Weinberg, Eugene
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2011, 22 (06) : 614 - 620
  • [24] Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study
    Allen, Ann
    Schenkenberger, Isabelle
    Trivedi, Roopa
    Cole, Jeremy
    Hicks, Wesley
    Gul, Nadeem
    Jacques, Loretta
    CLINICAL RESPIRATORY JOURNAL, 2013, 7 (04) : 397 - 406
  • [25] Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma
    Sorkness, CA
    LaForce, C
    Storms, W
    Lincourt, WR
    Edwards, L
    Rogenes, PR
    CLINICAL THERAPEUTICS, 1999, 21 (02) : 353 - 367
  • [26] Effects of Mometasone Furoate Administered Via a Dry Powder Inhaler Once Daily in the Evening on Nocturnal Lung Function and Sleep Parameters in Patients with Moderate Persistent AsthmaA Randomized, Double-Blind, Placebo-Controlled Pilot Study
    John H. Krouse
    Helene J. Krouse
    James J. Janisse
    Clinical Drug Investigation, 2009, 29 : 51 - 58
  • [27] Evaluation of hypothalamic-pituitary-adrenal axis suppression by low-dose (0.5 μg) and standard-dose (250 μg) adrenocorticotropic hormone (ACTH) tests in asthmatic children treated with inhaled corticosteroid
    Ozbek, Ozlem Yilmaz
    Turktas, Ipek
    Bakirtas, Arzu
    Bideci, Aysun
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2006, 19 (08) : 1015 - 1023